What is the preferred reliever medication for a 13-year-old female with asthma who experiences symptoms twice weekly according to Global Initiative for Asthma (GINA) guidelines?

Preferred Reliever Medication for This Patient

For this 13-year-old with asthma symptoms twice weekly, the preferred reliever medication according to current GINA guidelines is as-needed low-dose ICS-formoterol (inhaled corticosteroid combined with formoterol), not a short-acting beta-agonist (SABA) alone. 1, 2

Understanding the Clinical Context

This patient has mild persistent asthma based on symptom frequency (twice weekly). The 2019 GINA guidelines made a landmark shift away from SABA-only treatment at all severity levels, including mild asthma, due to mounting evidence of risks associated with SABA monotherapy and overuse 2.

GINA Track 1 (Preferred Approach)

The current GINA strategy divides treatment into two tracks, with Track 1 being the preferred option 1, 3:

• Reliever: As-needed low-dose ICS-formoterol at all steps
• For mild asthma (Steps 1-2): Use as-needed only
• This approach reduces severe exacerbations by ≥60% compared with SABA alone 2

Key Evidence Supporting This Recommendation

Large randomized trials demonstrate that as-needed combination ICS-formoterol in mild asthma achieves:

• Similar symptom control and lung function as daily ICS plus as-needed SABA
• Dramatically reduced exacerbation rates compared to SABA monotherapy
• Lower total corticosteroid exposure 2

A 2025 study specifically in adolescents aged 12 and older showed Track 1 patients had:

• Significantly fewer readmissions (4.65% vs. 19.15%, p=0.036)
• Fewer ER visits (1.69 vs. 2.8, p<0.001)
• Less intensive care requirement (9.3% vs. 27.66%, p=0.034)
• Better pulmonary function improvement at 3 months 4

Track 2 (Alternative Approach)

If ICS-formoterol combination is unavailable or unsuitable:

• Reliever: As-needed SABA
• Controller: Must be prescribed with separate low-dose ICS inhaler (not SABA alone)
• This is explicitly an alternative, not preferred option 1, 3

Critical Implementation Points

SABA monotherapy is no longer recommended at any asthma severity level 2. The older guidelines that recommended SABA alone for intermittent or mild asthma (such as those from 2007-2010 in the evidence provided 5, 6) have been superseded by more recent evidence.

Practical Prescribing

For this 13-year-old:

1. First choice: Prescribe low-dose budesonide-formoterol (the combination with the most data) to be used as-needed for symptom relief
2. Typical dosing: 1-2 puffs as needed for symptoms (off-label use in some countries) 1
3. Ensure proper inhaler technique training
4. Provide written asthma action plan 3

Common Pitfall to Avoid

Do not prescribe albuterol/salbutamol alone even though symptoms occur only twice weekly. This outdated approach increases exacerbation risk and is no longer guideline-concordant. Studies show only 2.4% of providers prescribe preferred reliever therapy, with most still using alternative approaches 7, indicating widespread non-adherence to current guidelines.

Why This Matters for Morbidity and Mortality

The shift to ICS-containing relievers addresses a critical safety issue: SABA overuse and SABA-only treatment are associated with increased severe exacerbations, hospitalizations, and asthma deaths 2. Even in mild asthma with infrequent symptoms, the anti-inflammatory component provides crucial protection against sudden severe exacerbations.